These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34370218)

  • 1. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Malik A; Nadeem M; Malik MI
    Clin J Gastroenterol; 2021 Dec; 14(6):1579-1586. PubMed ID: 34370218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 4. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
    Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.
    Malik A; Malik M; Qureshi S
    Can Liver J; 2024 Feb; 7(1):40-53. PubMed ID: 38505782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.
    Zhou J; Chen Y; Yu J; Li T; Lu Z; Chen Y; Zhang X; Ye F
    Medicine (Baltimore); 2021 Mar; 100(12):e24884. PubMed ID: 33761646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis.
    Malik A; Nadeem M; Amjad W; Malik MI; Javaid S; Farooq U; Naseem K; Khan A
    Prz Gastroenterol; 2023; 18(1):67-75. PubMed ID: 37007760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis.
    Goyal NP; Mencin A; Newton KP; Durelle J; Carrier C; Ugalde-Nicalo P; Noel B; Mouton J; Vargas D; Magrez D; Tadde B; Birman P; Best BM; Addy C; Schwimmer JB
    J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):160-165. PubMed ID: 37084342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W
    Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
    Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
    Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis.
    Li TH; Yang YY; Huang CC; Liu CW; Tsai HC; Lin MW; Tsai CY; Huang SF; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
    Clin Sci (Lond); 2019 Feb; 133(3):531-544. PubMed ID: 30602573
    [No Abstract]   [Full Text] [Related]  

  • 15. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A; Chew GT; Watts GF
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
    Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
    Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
    Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Marey MM; Belal M; Awad AA; Rabea EM; Hassan MA; Abbas AW; Nashwan AJ
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102357. PubMed ID: 38688423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.